Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia

Kimmo Porkka, Perttu Koskenvesa, Tuija Lundán, Johanna Rimpiläinen, Satu Mustjoki, Richard Smykla, Robert Wild, Roger Luo, Montserrat Arnan, Benoit Brethon, Lydia Eccersley, Henrik Hjorth-Hansen, Martin Höglund, Hana Klamova, Håvar Knutsen, Suhag Parikh, Emmanuel Raffoux, Franz Gruber, Finella Brito-Babapulle, Hervé DombretRafael F. Duarte, Erkki Elonen, Ron Paquette, C. Michel Zwaan, Francis Y.F. Lee

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

337 Citaten (Scopus)

Samenvatting

Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome-positive (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain barrier. Imatinib and dasatinib (a dual-specific SRC/BCR-ABL kinase inhibitor) were compared in a pre-clinical mouse model of intracranial Ph+ leukemia. Clinical dasatinib treatment in patients with CNS Ph+ leukemia was assessed. In preclinical studies, dasatinib increased survival, whereas imatinib failed to inhibit intracranial tumor growth. Stabilization and regression of CNS disease were achieved with continued dasatinib administration. The drug also demonstrated substantial activity in 11 adult and pediatric patients with CNS Ph+ leukemia. Eleven evaluable patients had clinically significant, long-lasting responses, which were complete in 7 patients. In 3 additional patients, isolated CNS relapse occurred during dasatinib therapy; and in 2 of them, it was caused by expansion of a BCR-ABL-mutated dasatinib-resistant clone, implying selection pressure exerted by the compound in the CNS. Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clinical activity in patients who experience CNS relapse while on imatinib therapy. This study is registered at ClinicalTrials. gov as CA180006 (#NCT00108719) and CA180015 (#NCT00110097).

Originele taal-2Engels
Pagina's (van-tot)1005-1012
Aantal pagina's8
TijdschriftBlood
Volume112
Nummer van het tijdschrift4
DOI's
StatusGepubliceerd - 15 aug. 2008
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit